Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

Highlights • Survival outcomes of patients with NSCLC without targetable mutations remain depressing. • Sintilimab plus docetaxel as second-line therapy improves progression-free survival outcomes. • Sintilimab plus docetaxel is safe and well-tolerated. • Patients detected with high PD-L1 expression...

Full description

Bibliographic Details
Main Authors: Yongchang Zhang, Lianxi Song, Liang Zeng, Yi Xiong, Li Liu, Chunhua Zhou, Haiyan Yang, Zhan Wang, Qing Xia, Wenjuan Jiang, Qinqin Xu, Nong Yang
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Cancer
Subjects:
Sintilimab plus docetaxel
NSCLC
CTC-PD-L1
Multiplex immunofluorescence
Online Access:https://doi.org/10.1186/s12885-022-10045-0

Internet

https://doi.org/10.1186/s12885-022-10045-0

Similar Items